Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]-chromen-2-one

Life Sciences

Volumn 86, Issue 21-22, 2010, Pages 819-824

  Vergel, Nadezdha E ^a   López, José L ^b   Orallo, Francisco ^c   Viña, Dolores ^c   Buitrago, Diana M ^a   del Olmo, Esther ^b   Mico, Juan A ^d   Guerrero, Mario F ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

Antidepressant; Coumarin; Drug design; MAO A; Monoamine oxidase

Indexed keywords

4 PROPYL 2H BENZO[H]CHROMEN 2 ONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; FCS 304; MONOAMINE OXIDASE A INHIBITOR; PENTETRAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FORCED SWIMMING TEST; IC 50; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; SEIZURE; SLEEP TIME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED ICR; MONOAMINE OXIDASE INHIBITORS; SEIZURES; SLEEP;

MUS;

EID: 77952673774     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.04.001     Document Type: Article

References (38)

1. Apseloff G., Hilliard J.B., Gerber N., Mays D.C. Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. Xenobiotica 1991, 21(11):1461-1471.
2. Ariza S.Y., Rincón J., Guerrero M.F. Efectos sobre el sistema nervioso central del extracto etanólico y fracciones de Hygrophila tyttha Leonard. Revista Colombiana de Ciencias Quimico Farmacéuticas 2006, 35(1):106-119.
3. Ariza S.Y., Rueda D.C., Rincón J., Linares E.L., Guerrero M.F. Efectos farmacológicos sobre el sistema nervioso central inducidos por cumarina, aislada de Hygrophila tyttha Leonard. VITAE 2007, 14(2):51-58.
4. Barreiro-Arcos M.L., Cremaschi G., Werner S., Coussio J., Ferraro G., Anesini C. Tilia cordata Mill extracts and scopoletin (isolated compound): differential cell growth effects on lymphocytes. Phytotherapy Research 2006, 20(1):34-40.
5. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33(1):87-107.
6. Bisagni E. Synthesis of psoralens and analogues. Journal of Photochemistry and Photobiology B: Biology 1992, 14(1-2):23-46.
7. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Reviews 2003, 9(1):97-140.
8. Catto M., Nicolotti O., Leonetti F., Carotti A., Favia A.D., Soto-Otero R., et al. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. Journal of Medicinal Chemistry 2006, 49(16):4912-4925.
9. Chen Y., Kong L.D., Xia X., Kung H.F., Zhang L. Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the forced swimming test in mice. Journal of Ethnopharmacology 2005, 96(3):451-459.
10. Costall B., Naylor R.J., Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacology, Biochemistry and Behavior 1989, 33(1):197-203.
11. Di Santo R., Costi R., Roux A., Artico M., Befani O., Meninno T., et al. Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors. Journal of Medicinal Chemistry 2005, 48(13):4220-4223.
12. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Archives of General Psychiatry 2007, 64(3):327-337.
13. Fylaktakidou K.C., Hadjipavlou-Litina D.J., Litinas K.E., Nicolaides D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Current Pharmaceutical Design 2004, 10(30):3813-3833.
14. Gnerre C., Catto M., Leonetti F., Weber P., Carrupt P.A., Altomare C., et al. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. Journal of Medicinal Chemistry 2000, 43(25):4747-4758.
15. Holmes G.L., Zhao Q. Choosing the correct antiepileptic drugs: from animal studies to the clinic. Pediatric Neurology 2008, 38(3):151-162.
16. Howes M., Perry N., Houghton P. Plants with traditional uses and activities relevant to the management of Alzheimer's disease and other cognitive disorders. Phytotherapy Research 2003, 17(1):1-18.
17. Jones B.J., Roberts D.J. The quantitative measurement of motor incoordination in naive mice using an accelerating rotarod. Journal of Pharmacy and Pharmacology 1968, 20(4):302-404.
18. Kang S.Y., Lee K.Y., Sung S.H., Kim Y.C. Four new neuroprotective dihydropyranocoumarins from Angelica gigas. Journal of Natural Products 2005, 68(1):56-59.
19. Kupferberg H.J., Schmutz M. Screening of new compounds and the role of the pharmaceutical industry. Epilepsy A Comprehensive Textbook 1997, 1417-1434. Lippincott-Raven, Philadelphia. J. Engel, T.A. Pedley (Eds.).
20. Lapa AJ, Souccar C, Lima MT, Lima TCM. Métodos farmacológicos para el estudio de actividad sobre el sistema nervioso central. In: CYTED/CNPq (Ed), Métodos de evaluación de la actividad farmacológica de plantas medicinales. Florianópolis, Santa Catarina, pp 70-90, 2002.
21. McGrath P.J., Stewart J.W., Harrison W., Quitkin F.M. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor. Psychopharmacology Bulletin 1987, 23(1):169-172.
22. Meotti F.C., Ardenghi J.V., Pretto J.B., Souza M.M., d' Avila Moura J., Junior A.C., et al. Antinociceptive properties of coumarins, steroid and dihydrostyryl-2-pyrones from Polygala sabulosa (Polygalaceae) in mice. Journal of Pharmacy and Pharmacology 2006, 58(1):107-112.
23. Micó J.A., Ardid D., Berrocoso E., Eschalier A. Antidepressants and pain. Trends in Pharmacological Sciences 2006, 27(7):348-354.
24. NTP toxicology and carcinogenesis studies of coumarin (CAS No. 91-64-5) in F344/N rats and B6C3F1 mice (Gavage Studies). National Toxicology Program Technical Report Series 1993, 422:1-340. National Toxicology Program.
25. Ojala T. Biological Screening of Plant Coumarins 2001, Faculty of Science of the University of Helsinki, Yliopistopaino, Helsinki, Chapter 2.
26. Payá M., Halliwell B., Hoult J.R. Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. Biochemical Pharmacology 1992, 44(2):205-214.
27. Pieters L., Vlietinck A.J. Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds?. Journal of Ethnopharmacology 2005, 100(1-2):57-60.
28. Porsolt R.D., Bertini A., Jalpe M. Behavioral despair in mice: a preliminary screening test for antidepressants. Archives of International Pharmacodynamy 1977, 229:327-336.
29. Potdar M.K., Mohile S.S., Salunkhe M.M. Coumarin syntheses via Pechmann condensation in Lewis acidic chloroaluminate ionic liquid. Tetrahedron Letters 2001, 42(52):9285-9287.
30. Rehman S.U., Chohan Z.H., Gulnaz F., Supuran C.T. In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. Journal of Enzyme Inhibition and Medicinal Chemistry 2005, 20(4):333-340.
31. Rendenbach-Müller B., Schlecker R., Traut M., Weifenbach H. Synthesis of coumarins as subtype-selective inhibitors of monoamine oxidase. Bioorganic and Medicinal Chemistry Letters 1994, 4(10):1195-1198.
32. Roux S, Sablé E, Porsolt RD. Primary Observation (Irwin) Test in Rodents for Assessing Acute Toxicity of a Test Agent and its Effects on Behavior and Physiological Function. In: John Wiley and Sons (Ed), Current Protocols in Pharmacology, pp 10.10.01-10.10.23, 2003.
33. Santana L., Uriarte E., González-Díaz H., Zagotto G., Soto-Otero R., Méndez-Alvarez E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. Journal of Medicinal Chemistry 2006, 49(3):1149-1156.
34. Santana L., González-Díaz H., Quezada E., Uriarte E., Yáñez M., Viña D., Orallo F. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of Medicinal Chemistry 2008, 51(21):6740-6751.
35. Steru L., Cherman R., Thierry B., Simon P. The tail suspension test: a new method for screening of antidepressants in mice. Psychopharmacology 1985, 85(3):367-370.
36. Swinyard E., Woodhead J., White H., Franklin M. Experimental selection, quantification, and evaluation of anticonvulsants. Antiepilectic Drugs 1989, 85-102. New York. R. Levy (Ed.).
37. Thull U., Testa B. Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochemical Pharmacology 1994, 47(12):2307-2310.
38. Yun B.S., Lee I.K., Ryoo I.J., Yoo I.D. Coumarins with monoamine oxidase inhibitory activity and antioxidative coumarino-lignans from Hibiscus syriacus. Journal of Natural Products 2001, 64(9):1238-1240.